Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience

Clinical Lymphoma, Myeloma and Leukemia

Volumn 16, Issue 6, 2016, Pages e79-e84

  Jimenez Zepeda, Victor H ^a   Duggan, Peter ^a   Neri, Paola ^a   Bahlis, Nizar J ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

AL amyloidosis; Bortezomib; Cardiac response; CyBorD; Hematologic response

Indexed keywords

BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; AMYLOID PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMYLOID LIGHT CHAIN AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; ASCITES; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEART FAILURE; HUMAN; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; SEVERE RENAL IMPAIRMENT; TREATMENT DURATION; TREATMENT RESPONSE; COMORBIDITY; METABOLISM; MORTALITY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOGENIC PROTEINS; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BORTEZOMIB; COMORBIDITY; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; RECURRENCE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84974633294     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2016.03.005     Document Type: Article

References (19)

1. A. Dispenzieri, F. Buadi, S.K. Kumar, and et al. Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement Mayo Clin Proc 90 2015 1054 1081
2. A.D. Wechalekar, J.D. Gillmore, J. Bird, and et al. Guidelines on the management of AL amyloidosis Br J Haematol 168 2015 186 206
3. M.T. Cibeira, and J. Blade Upfront CyBorD in AL amyloidosis Blood 126 2015 564 566
4. J.R. Mikhael, S.R. Schuster, V.H. Jimenez-Zepeda, and et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis Blood 119 2012 4391 4394
5. C.P. Venner, T. Lane, D. Foard, and et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival Blood 119 2012 4387 4390
6. G. Palladini, P. Milani, A. Foli, and et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients Leukemia 28 2014 2311 2316
7. G. Palladini, A. Foli, P. Milani, and et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure Am J Hematol 87 2012 465 471
8. A. Jaccard, R.L. Comenzo, P. Hari, and et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) Haematologica 99 2014 1479 1485
9. G. Palladini, A. Dispenzieri, M.A. Gertz, and et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes J Clin Oncol 30 2012 4541 4549
10. M.A. Gertz, R. Comenzo, R.H. Falk, and et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004 Am J Hematol 79 2005 319 328
11. S.T. Pellom Jr., D.F. Dudimah, M.C. Thounaojam, T.J. Sayers, and A. Shanker Modulatory effects of bortezomib on host immune cell functions Immunotherapy 7 2015 1011 1022
12. M. Rosenzweig, S. Giralt, and H. Landau Light-chain amyloidosis: SCT, novel agents and beyond Bone Marrow Transplant 48 2013 1022 1027
13. D.E. Reece, U. Hegenbart, V. Sanchorawala, and et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study Blood 118 2011 865 873
14. D.E. Reece, U. Hegenbart, V. Sanchorawala, and et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis Blood 124 2014 2498 2506
15. E. Kastritis, A.D. Wechalekar, M.A. Dimopoulos, and et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis J Clin Oncol 28 2010 1031 1037
16. G. Palladini, S. Sachchithanantham, P. Milani, and et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis Blood 126 2015 612 615
17. A. Wechalekar, C. Whelan, S. Sachchithanantham, and et al. A matched case control study of doxycycline added to chemotherapy for reducing early mortality in patients with advanced cardiac AL amyloidosis from the Alchemy Study Cohort Blood 124 2014 3485
18. D.B. Richards, L.M. Cookson, A.C. Berges, and et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component N Engl J Med 373 2015 1106 1114
19. M. Gertz, H. Landau, R. Comenzo, and et al. Cardiac and renal biomarker response in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction J Clin Oncol 33 suppl 2015 abstract 8514